Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series B financing round, following a USD 37 million Series A funding in July this year. This latest round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, along with continued support from existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital. The proceeds will be allocated to boost clinical studies for AHB-137, AusperBio’s lead investigational therapy, in China and globally, as well as to support its early commercialization, new pipeline expansion, and team development.
AusperBio’s Focus on Chronic Hepatitis B Infection and Pipeline Expansion
AusperBio is dedicated to the research and development of oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection. The company’s proprietary Med-Oligo ASO platform has led to the development of AHB-137, a novel unconjugated antisense oligonucleotide (ASO) designed to treat chronic hepatitis B with the aim of achieving a functional cure. AHB-137 has been granted Breakthrough Therapy Designation in China, recognizing its potential to significantly improve patient outcomes.
The Impact of Funding on AusperBio’s Development and Commercialization Efforts
The Series B funding will play a crucial role in advancing the clinical development of AHB-137 and expanding AusperBio’s pipeline. It will also support the early commercialization of the therapy, positioning the company to bring innovative treatments to patients suffering from chronic hepatitis B and other liver diseases. The investment in team development will further strengthen AusperBio’s capabilities in delivering on its mission to transform liver therapies.-Fineline Info & Tech
